Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Spyre Therapeutics (SYRE) and Ionis Pharmaceuticals (IONS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teladoc (TDOC – Research Report), Spyre Therapeutics (SYRE – Research Report) and Ionis Pharmaceuticals (IONS – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Teladoc (TDOC)
Citi analyst Daniel Grosslight maintained a Hold rating on Teladoc yesterday and set a price target of $9.00. The company’s shares closed last Wednesday at $4.65.
According to TipRanks.com, Grosslight is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Teladoc with a $8.08 average price target, which is a 74.9% upside from current levels. In a report issued on February 18, BTIG also maintained a Hold rating on the stock.
See today’s best-performing stocks on TipRanks >>
Spyre Therapeutics (SYRE)
In a report released yesterday, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Spyre Therapeutics, with a price target of $64.00. The company’s shares closed last Wednesday at $43.88.
According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spyre Therapeutics with a $58.71 average price target, representing a 32.9% upside. In a report issued on February 20, Citi also maintained a Buy rating on the stock with a $64.00 price target.
Ionis Pharmaceuticals (IONS)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Ionis Pharmaceuticals yesterday and set a price target of $100.00. The company’s shares closed last Wednesday at $80.93.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ionis Pharmaceuticals with a $98.55 average price target, which is a 20.6% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
